Jacobs Levy Equity Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Jacobs Levy Equity Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,805	Closed	-$285K	–	1140
2022 Q1	$285K	Sell	12,805 -1,934	-13%	-$49.4K	﹤0.01%	928
2021 Q4	$644K	Buy	14,739 +1,448	+11%	+$57.9K	﹤0.01%	802
2021 Q3	$443K	Sell	13,291 -19,373	-59%	-$589K	﹤0.01%	880
2021 Q2	$899K	Buy	32,664 +2,243	+7%	+$46.7K	0.01%	759
2021 Q1	$611K	Buy	+30,421	New	+$888K	﹤0.01%	829

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's INBX Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2022, closing a stake of 12,805 shares — an estimated $285K sold.

Jacobs Levy Equity Management first reported a position in INBX in Q1 2021 and held it in 5 quarters. The position peaked at $899K in Q2 2021. 100 funds tracked by Wall St. Rank hold INBX as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 12,805 Inhibrx, Inc. Common Stock shares in Q2 2022, an estimated $285K.
Jacobs Levy Equity Management first reported a position in Inhibrx, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Jacobs Levy Equity Management's Inhibrx, Inc. Common Stock position peaked at $899K in Q2 2021.
100 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.